Any way you cut it, Rockwell Medical (NASDAQ: RMTI) stock is having a rocky year.
With little revenue to support it, and no profits whatsoever, this small-cap biopharmaceuticals maker is largely subject to the whims of investors who either love it or hate it — or both, depending on the day of the week. Right now, these investors have sold short 19% of Rockwell’s float.